Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2025-11-20 00:00:00 ET · period of report 2025-11-18 · accession 0001614740-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-20 | 2025-11-18 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $19.24 | +19.1K | 158.0K | +14% | +$368.1K |
| D | 2025-11-20 | 2025-11-18 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $0.00 | -19.1K | 150.9K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-18 | M | A | 19,133 | $19.24 | 158,034 | D | — | — | (F1) Includes 260 shares of Common Stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-11-18 | M | D | 19,133 | $0.00 | 150,867 | D | $19.24 · — to 2030-01-09 | 19,133 Common Stock | (F2) The stock option is fully vested. |